Thyroid Hormone Receptor-β Agonists in NAFLD Therapy: Possibilities and Challenges

Area of Science:

• Hepatology
• Endocrinology
• Pharmacology

Background:

• Nonalcoholic fatty liver disease (NAFLD) is a prevalent metabolic disorder lacking specific FDA-approved treatments.
• Thyroid hormone plays a crucial role in regulating metabolism, and hypothyroidism is a risk factor for NAFLD.
• Thyroxine, a thyroid hormone, reduces liver fat in animal models but causes cardiac side effects.

Approach:

• Investigating thyroid hormone receptor (TR) subtypes, specifically TRβ, which is predominantly expressed in the liver.
• Developing TRβ-specific agonists to selectively target liver function and mitigate cardiac adverse effects.
• Reviewing current TRβ-specific agonists that have demonstrated therapeutic potential in NAFLD models and advanced to clinical trials.

Key Points:

• TRβ agonists offer a targeted approach to NAFLD treatment by activating liver-specific metabolic pathways.
• Selective TRβ activation aims to prevent the cardiac side effects associated with non-selective thyroid hormone administration.
• Several TRβ agonists are progressing through clinical trials, indicating significant therapeutic promise for NAFLD.

Conclusions:

• TRβ-specific agonists represent a promising therapeutic strategy for managing NAFLD.
• Targeting TRβ may provide an effective and safer alternative to conventional treatments for metabolic liver disease.
• Further research and clinical evaluation of TRβ agonists are essential for their future application in NAFLD treatment.